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Abstract
Background—Timely initiation of combination antiretroviral therapy (ART) in eligible HIV-
infected patients is associated with substantial reductions in mortality and morbidity. Nigeria has
the second largest number of persons living with HIV/AIDS in the world. We examined patient
characteristics, time to ART initiation, retention and mortality at five rural facilities in Kwara and
Niger states of Nigeria.
Methods—We analyzed program-level cohort data for HIV-infected, ART-naïve clients (≥15
years) enrolled from June 2009-February 2011. We modeled the probability of ART initiation
among clients meeting national ART eligibility criteria using logistic regression with splines.
Results—We enrolled 1,948 ART-naïve adults/adolescents into care, of whom 1174 were ART
eligible (62% female). Only 74% of eligible patients (n=869) initiated ART within 90 days post-
enrollment. The median CD4+ count for eligible clients was 156 cells/μL [IQR: 81–257], with
67% in WHO stage III/IV disease. Adjusting for CD4+ count, WHO stage, functional status,
hemoglobin, body mass index, sex, age, education, marital status, employment, clinic of
attendance, and month of enrollment, we found that immunosuppression (CD4 350 vs. 200, odds
ratio (OR)=2.10 [95%CI: 1.31, 3.35], functional status (bedridden vs. working, OR=4.17 [95%CI:
1.63–10.67]), clinic of attendance (Kuta hospital vs. referent: OR=5.70 [95%CI:2.99–10.89]), and
date of enrollment (December 2010 vs. June 2009: OR=2.13 [95%CI:1.19–3.81]) were associated
with delayed ART initiation.
Conclusion—Delayed initiation of ART was associated with higher CD4+ counts, lower
functional status, clinic of attendance, and later dates of enrollment among ART-eligible clients.
Our findings provide targets for quality improvement efforts that may help reduce attrition and
improve ART uptake in similar settings.
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INTRODUCTION
Nigeria is home to the second-largest number of people living with HIV in the world (est.
3.3 million), after South Africa.1,2 The U.S. President's Emergency Plan for AIDS Relief
(PEPFAR) has made substantial contributions to stemming the tide of the HIV/AIDS
epidemic in Nigeria, but there is still much to be done. While PEPFAR supported provision
of comprehensive antiretroviral treatment (ART) to 334,700 Nigerians in 2010, national
treatment coverage from all sources was 26%, the lowest among all 15 PEPFAR focus
countries.3 Similarly, only 14.7% of 3351 health facilities nationwide offered ART services
in 2011, despite a 25% increase (from 393 to 491) in the number of ART sites between 2009
and 2011.4 The ability to access HIV treatment services beyond larger cities remains
limited.3–6
Adding to the problem of lack of access to ART are delays in initiation of ART in treatment-
eligible patients. Delays in initiation of ART could be due to many reasons, including pre-
ART attrition and system-mandated waits to allow for pre-treatment counseling.7–9 These
delays are associated with excess rates of preventable morbidity and mortality, especially in
ART-eligible patients with advanced HIV disease who are already at elevated risk of
death.10–13 Compared to studies on adherence and retention after commencement of ART,
there is a relative dearth of literature on factors associated with delayed ART initiation in the
pre-ART phase.10 Such research could contribute to the development of programmatic
strategies to minimize holdups in treatment initiation, thereby curtailing high levels of early
mortality seen in HIV-infected patients in resource-limited settings.14,15
In addition to few studies of delayed ART initiation, there is little published operations
research on programmatic trends and outcomes of HIV-infected patients enrolled in rural
HIV treatment programs in Nigeria.5–,6,16 Lessons learned in rural settings may differ
substantially from what has been learned in peri-urban and urban settings, thus providing
valuable information to policymakers as service provision is scaled-up in secondary-level
health facilities.16--18
This study reviewed baseline characteristics of adults enrolled in HIV care and treatment in
an ART program in north-central Nigeria. Predictors of delayed initiation of ART, i.e.,
initiation of ART more than 90 days after enrollment into HIV care and treatment and trends
in mortality and retention in care were also examined.
METHODS
Study design
This is an observational cohort study using patient-level data routinely collected for program
monitoring and evaluation purposes.
Study setting
Since 2008, the Vanderbilt Institute for Global Health (VIGH) and its non-governmental
Nigerian incorporated affiliate, Friends in Global Health, LLC (FGH), have been
implementing comprehensive HIV/AIDS services focused in rural Kwara and Niger states,
with funding from PEPFAR through the U.S. Centers for Disease Control and Prevention
(CDC). Niger and Kwara states are located in Nigeria's north central region bordering the
country of Benin on the west. The north central region has the highest HIV prevalence in the
country (2010 adult HIV prevalence of 7.5% vs. national HIV prevalence of 3.6%).10 Both
Ilorin, the capital of Kwara State and Minna, capital of Niger State are located on major
highways that link the north and south of Nigeria, with substantial populations of HIV at-
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risk groups. The prevalence of HIV among adults in Niger and Kwara states is estimated to
be 4.0% and 2.2%, respectively.19
As of mid 2011, VIGH/FGH supported HIV/AIDS services in five secondary-level facilities,
namely: Sobi Specialist Hospital (Ilorin) and Lafiagi General Hospital in Kwara state; and
Gawu Babangida Rural Hospital, Kuta Rural Hospital, and Umaru Yar Adua Hospital Sabon
Wuse in Niger State. These five clinics are served by nine rural HTC/PMTCT feeder sites
(`satellite' sites) in a hub and spoke model.
Study population
This study included all HIV-infected patients aged ≥15 years of both sexes entering HIV
care and treatment in VU/FGH-supported treatment sites from June 1, 2009 through
February 28, 2011. Study exclusion criteria included patients <15 years old and patients
enrolled into care outside the defined study period.
Care and treatment protocol
VIGH/FGH-supported activities in Nigeria utilize an integrated and holistic health system
strengthening approach, organized around two core principles: 1) direct technical assistance
to government health facilities to implement integrated HIV clinical services at the state
level; and 2) health workforce capacity development. Supported activities include the
following program areas: adult and pediatric HIV care and treatment, prevention of mother-
to-child HIV transmission (PMTCT), HIV testing and counseling (HTC), tuberculosis (TB)-
HIV services, orphans and vulnerable children, pharmaceutical logistics including
procurement and provision of antiretroviral drugs, strengthening of laboratory infrastructure,
and improvement of strategic information services.
Patients who tested HIV-positive in VIGH/FGH-supported clinics, or who were referred
from other clinics, were enrolled into the HIV care and treatment program. HIV testing
occurred in HTC, PMTCT or TB settings using the national serial rapid HIV testing
algorithm. All enrolled patients received an initial evaluation, including baseline lab tests
(CD4+ cell counts [CD4+ counts], hematology, chemistry), WHO clinical staging and a
general clinical exam by a physician to screen for TB and other opportunistic infections.
Clients received a basic care kit and other services, including adherence counseling,
nutritional support, palliative care, and home-based care (based on need).
Enrolled adult patients were deemed eligible for ART based on Nigerian guidelines. Prior to
June 2010, initiation guidelines included all patients with WHO stage I/II disease with
CD4+ cells <200/μL, or with WHO stage III disease and CD4+ cells 200–350/ μL, or WHO
stage IV disease regardless of CD4+ cell count. Beginning June 2010, initiation guidelines
included having a CD4+ cell count <350/μL; or having WHO stage III or IV disease
regardless of CD4+ cell count. The most commonly used adult ART regimen was a
combination of zidovudine [ZDV] plus lamivudine [3TC] plus nevirapine [NVP] or
efavirenz [EFV] (nonpregnant clients). Some clients received tenofovir [TDF] in place of
ZDV and emtricitabine [FTC] instead of 3TC. Patients requiring second-line ART were
placed on two new nucleoside reverse transcriptase inhibitors (NRTIs) plus the protease
inhibitor lopinavir/ritonavir. Pregnant women with WHO stage III or IV disease and/or
having a CD4+ cell count <350 cells/μL were immediately referred to treatment sites for
ART initiation. Non-pregnant patients were followed up in clinic every 3 months. The
specific care and treatment protocol for children is outside the scope of this study.
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Data Source, Cleaning and Measurement
We used routinely collected PEPFAR program data for this analysis. The database was
extracted on 31 May 2011 such that all patients enrolled on or before 28 February 2011
could contribute data for evaluation of ART initiation within 90 days of enrollment. After
each clinic day, FGH data clerks entered data from national patient management and
monitoring (PMM) forms that had been completed by clinicians, nurses, laboratory, and
pharmacy staff into CAREWare™ (JPROG, New Orleans, LA), an electronic medical
records system. Routine audits of medical records were performed to ensure that forms were
completed accurately and laboratory data were entered correctly. Demographic information
was based on self-report and included: sex, age, marital status, educational status,
occupational status, and service entry into the program. Clinical and laboratory data
included: weight, height, functional status, WHO clinical stage, TB status, CD4+ cell count,
hepatitis B surface antigen and syphilis (VDRL) serology, pregnancy status, hematocrit,
hemoglobin, alanine aminotransferase (ALT), and creatinine levels.
Data queries were generated for out-of-range and missing data. Each site addressed its data
queries; clean data were extracted for the final analyses. We indicated the following out-of-
range data for laboratory and anthropometric values as missing, based on consensus of our
expert team of senior clinicians: hemoglobin <1 (n=46) and >18 (n=60); CD4+ cell count <0
(n=0) or >1500 (n=7); creatinine >100 mg/dL (n=10) or <0.1 mg/dL (n=0); height <100 cm
(n=21) or >220 cm (n=4); weight <20 kg (n=23) or >120 kg (n=19). Extreme body mass
index (BMI) records <10 kg/m2 (n=11) and >50 kg/m2 (n=38) were also considered out of
range and therefore missing.
Definitions
Loss to follow-up (LTFU) was defined as those patients that are not deceased and have not
had contact in 180 days prior to closure of the database; this definition adheres to the
Nigeria and WHO policy standard of >90 days late for scheduled visit following a 3 month
routine visit schedule.20,21 Patients who tested HIV-positive, received post-test counseling
and had their information recorded in the clinic register were considered “enrolled into
care”. Enrolled patients were considered to have `initiated' treatment once they were started
on ART by a provider. Mortality was ascertained by facility records and tracking reports
from home-based care and community health workers.21
Outcomes
Our primary outcome was ART initiation within 90 days of enrollment among those eligible
for ART. The secondary endpoints included trends in rates of loss to follow up and
mortality. We employed an “intent-to-continue treatment” approach for all analyses
(disregarding subsequent changes to treatment, including treatment interruptions and
terminations), such that this represents a best-case scenario.
Statistical analysis
To describe patients who fail to initiate ART among those eligible for ART we tabulated
summary characteristics by ART initiation status within 90 days of enrollment. We used chi-
square and Wilcoxon rank sum tests to examine differences in baseline characteristics by
ART initiation status. We used a Kaplan-Meier plot and log-rank test to examine sex
differences in timely ART initiation. A multivariable logistic regression model assessed
whether baseline demographics, lab results, and clinical assessment were associated with
delayed ART initiation among clients meeting national ART eligibility criteria at
enrollment. To relax linearity assumptions, we modeled CD4+ counts and date of enrollment
using restricted cubic splines. Multiple imputation was used to account for missing values of
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baseline predictors and to prevent case-wise deletion of missing data; 418 (36%) patients
had complete data for all covariates. Covariates were identified a priori; those with more
than 60% missing were excluded from multivariable analysis. We used the functions
`aregImpute' and `fit.mult.impute' from the Hmisc package in R which used predictive mean
matching to take random draws from imputation models; 25 imputation data sets were used
in the analysis. Missing data is assumed to be missing at random conditional on the observed
outcome and non-missing covariates; all variables used in the logistic regression outcome
model were included in the imputation models. All hypothesis testing was two-sided with a
level of significance set at 5%. We employed R-software 2.15.1 (www.r-project.org) for all
data analyses. Analysis scripts are available at http://biostat.mc.vanderbilt.edu/
ArchivedAnalyses
Ethical considerations
This study included retrospective analysis of routinely collected service data and did not
involve any patient contact. Participants were not required to provide written informed
consent. All personal identifiers were removed after data abstraction. Data personnel were
trained on confidentiality and secure data transmission. Ethical approval was obtained from
the Vanderbilt University Institutional Review Board and the Nigeria National Human
Research Ethics Committee. Clearance from the Office of the Assistant Director of Science,
CDC Atlanta was also obtained.
RESULTS
From June 1, 2009 to February 28, 2011 we enrolled 1,948 HIV-infected adult patients into
care (Figure 1). Of the 1,673 HIV-infected adults assessed for ART eligibility within 90
days of enrollment, 1174 were deemed eligible. Of this number, 869 (74%) initiated ART
within the first 90 days following enrollment.
Sociodemographic and clinical characteristics
The majority of ART-eligible patients were female (62%).Slightly more than half of all
ART-eligible patients were enrolled at Gawu Babangida Rural Hospital (58%) [Table 1].
The median age (interquartile range, IQR) of eligible patients was 34 years (28–40). Many
ART-eligible patients were unemployed (55%) and illiterate (38%). Married persons
comprised 78% of all ART eligible patients. We found 6% of women in the cohort (n=66) to
be pregnant at enrollment. `Early' and `late/none' ART initiation groups were similar across
age, sex, educational level and marital status. Pregnant females initiated ART within 90 days
of enrollment at a more rapid rate than non-pregnant women and men (log rank test
P<0.001, Figure 2).
Clinical characteristics of the cohort are shown in Table 2. Median CD4+ cell count at
enrollment were 156/μL (IQR: 81–257). Median CD4+ cell counts and hemoglobin levels
were similar between early and late/none ART status categories. The median (IQR) values
for CD4+ cell counts and hemoglobin were 149/μL (69–282) and 10.2 g/dL (8.8–11.8),
respectively, for eligible patients who did not initiate ART within 90 days of enrollment.
Two-thirds of all patients (67%) had advanced HIV disease at enrollment (WHO stage III or
IV disease). Clients who did not initiate ART within 90 days were more likely to present
with severe clinical illness than those who did (proportion of delayed ART initiators with
WHO stage IV disease = 8% vs. 4% of early initiators, P<0.01).
Predictors of ART initiation
Table 3 shows logistic regression results for demographic and clinical predictors of delayed
ART initiation in all treatment eligible patients (including pregnant women). Clinic of
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enrollment and time of enrollment were strongly predictive of delayed ART initiation
(p<0.001). In general, patients enrolled at a more recent period were more likely to have
delayed ART initiation beyond 90 days of enrollment than those enrolled at the beginning of
the project (December 2010 vs. June 2009, OR=2.13 [95%CI: 1.19–3.81]). Patients who
were less functionally active were more likely to delay initiating treatment; bedridden clients
had a 4-fold odds of delayed treatment initiation compared with their counterparts who were
still working at the time of enrollment (OR: 4.17, 95% CI: 1.63–10.7). Lower BMI and
higher CD4+ counts were also independent predictors of delayed ART initiation. For every
unit increase in BMI, we observed a 7% decrease in odds of delayed ART, such that an
individual with BMI of 18.5 vs. 25 kg/m2 has 63% higher odds of delayed initiation (OR:
1.63, 95% CI: 1.13–2.34). The relationship between CD4+ cell count and log-odds of
delayed infection was U-shaped with a trough at 165 cells/ μL - patients having advanced
(CD4+ cell count <50/μL) and moderate levels of immunosuppression (about 250 cells/ μL)
at the time of enrollment had equal probability of delayed initiation. A HIV-infected patient
with CD4+ cell count of 350/μL had half the odds of delayed treatment than a patient having
a CD4+ cell count of 200/μL (OR: 2.10, 95% CI: 1.31–3.35). We found no evidence of an
independent association between WHO stage and treatment initiation. Associations
remained unchanged after pregnant women were excluded from the analysis (data not
shown).
Retention and Mortality
More than one-third of patients (39%) enrolled into the program and not initiating treatment
within 90 days were LTFU in 12 months; 49% of this LTFU occurred after the first visit.
The proportion of clients deemed LTFU was larger among delayed initiators than among
those who commenced ART within 90 days of enrollment (39% vs. 29% respectively,
P<0.01). Approximately 7% of patients who did not initiate treatment within 90 days were
confirmed deceased within 1 year of enrollment (versus 3% of those who started ART,
P<0.001).
DISCUSSION
Our experience in Nigeria indicates the feasibility of successfully implementing and rapidly
scaling up treatment services in rural north central Nigeria. However, outcomes are sub-
optimal. Prior to 2008, there was no ART-based HIV care at these sites. A sizeable
proportion of our patients were found to have advanced disease (WHO stage III/IV) at
enrollment, a finding that suggests that testing and linkage is not well implemented at the
community level. However, the proportion of patients having very advanced clinical disease
(WHO stage IV) showed a progressive decrease with program maturation, an encouraging
sign that we are accessing patients earlier who have less advanced disease.
We found a preponderance of females and unemployed persons among our patient cohort,
many of whom were also illiterate. The demographic characteristics of the clients in our
program reflect the sociocultural milieu of these communities. The rural northern part of
Nigeria has lower educational attainment and higher poverty rates than the southern part of
the country.22 Women and girls comprise 60% of people living with HIV in sub-Saharan
Africa; in Nigeria an estimated 1.7 million women over the age of 15 are HIV infected.2 It is
therefore not surprising that we have more women than men in our program; as seen in
Nigeria and elsewhere, PMTCT is a bridge for women to link to their own chronic HIV care
needs.16,23–26 Novel approaches to recruit more men into testing and care are
needed.14,27–29
There are few studies evaluating retention and clinical outcomes (including LTFU and
mortality) from Nigeria.5,6,16,21 We found substantial LTFU rates among our patients (33%
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by 12 months post enrollment), higher among clients who did not initiate treatment within
90 days of enrollment (39% at 12 months). A possible contributor to our high LTFU rates is
our non-utilization of pharmacy data to ascertain LTFU. Some clients could have picked up
their medications without having a clinical encounter, thereby erroneously becoming
classified as LTFU. We think this unlikely due to the dearth of alternative sources of
medications in these rural areas. We note similarly reported high rates of LTFU at 12
months in such diverse venues as large urban facilities in Abuja (34%),30 Benin, Calabar,
Enugu and Kano (25%)24 and rural/urban Southeast Nigeria (30%).23 There is a need for
well-designed HIV treatment retention and attrition studies in Nigeria that will provide valid
estimates for LTFU and other outcomes.6 We also need field surveys of LTFU clients; such
surveys in Uganda have been helpful in determining which LTFU are alive in care
elsewhere, alive but not in care, and deceased.31 A uniform definition for LTFU would be
helpful for PEPFAR, the Global Fund to fight HIV, Tuberculosis and Malaria, and other
Nigerian programs to permit performance to be compared fairly across in-country treatment
programs.32,33 However, different LTFU definitions may have to be used for different
purposes.34
We believe that certain program structural features help explain missing data. The first visit
was the only visit that took place in half of LTFU cases who were enrolled and did not
initiate treatment within 90 days (i.e., half of patients eligible for ART who were LTFU
never showed up for their second visit). CD4+ results are often provided to the patient at the
second visit; therefore a sizeable proportion of our eligible clients would not have known
that they were eligible for ART. Point-of-care CD4+ testing in rural sites may help to
address this awareness gap and reduce early attrition.35,36 Our programs should also
consider early patient tracking and adherence efforts to be important for all patients, not
merely those who have initiated ART. The aforementioned Abuja study made a similar case
for early tracing of defaulters, since two-thirds of documented deaths in their cohort
occurred within 3 months of enrollment.23
Our finding that death was more likely to occur in late treatment initiators than among
patients started on ART within 90 days of enrollment is expected.37–39 Two thirds of our
clients (67%) had advanced HIV disease (WHO stage III or IV) at the time of enrollment.
Reports that the majority of deaths in treatment programs occur in the months immediately
following ART initiation are well-documented.40–42 We cannot confirm this in this study, as
our mortality numbers are small, yielding unstable estimates.
Factors that were independently associated with delayed ART initiation in this study
included: more recent period of enrollment, clinic, lower function/higher disability status,
lower BMI and higher CD4+ cell counts. Unfortunately, as our treatment program matured,
newly enrolled patients were less and less likely to be initiated on ART. The higher risk of
delayed ART initiation as our program matured could be due to at least two factors. First,
we underwent significant changes in program leadership in the second year of the program
which reduced the intensity of staff supervision and mentoring as well as logistics
coordination (specifically laboratory [CD4+ cell count, chemistry, and hematology/CBC
draws] and pharmacy [ART medication stocks] issues). Second, we transitioned experienced
FGH clinicians from direct patient care responsibilities to technical assistance in the second
year of program implementation, which resulted in less experienced clinicians taking on
more direct patient care. These changes could have cumulatively affected the quality of
services provided, including ART-related decision-making and early tracking of newly-
enrolled patients. Since 91% of timely initiators had high functional status versus 82% of
late initiators, we confirm that the sickest patients are not necessarily those going on ART at
the highest rates in rural north central Nigeria. A reason could be the delay in commencing
ART that is sometimes associated with the need to first provide nutritional supplementation
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in markedly ill-looking or malnourished patients or with the clinicians' inclinations to wait
until treatment for TB and other OIs is commenced. Clients at Gawu Babangida Rural
Hospital were more likely to be initiated on ART; it was our first treatment center in Niger
state and is readily accessible to FGH staff in Abuja, facilitating closer oversight and easier
access to lab and pharmacy resources. In contrast, our most remote treatment site (Kuta
hospital) had the worst outcomes.
This study, grounded in real-world data, has several limitations. We had substantial amounts
of missing data, especially for core sociodemographic variables. We were also unable to
determine eligibility for patients missing CD4+ cell counts with WHO stage I and II disease
(and III before June 2010), whereas this determination was straightforward for patients
having WHO stage IV disease (and III after June 2010) who were all eligible for treatment.
Since those patients without CD4+ counts were not included in the denominator, the
proportion of patients we report as ART eligible could be an overestimate. The mortality
statistics presented here are an underestimate, as some LTFU patients are deceased. A major
strength of this study is our use of multiple clinics in real-world, rural Nigeria, reflecting the
realities of PEPFAR implementation for a rural, under-studied population. Other strong
points include: large sample size, use of an extensive querying and data cleaning process and
the application of multiple imputation to account for missing values of baseline predictors
and to prevent case-wise deletion of missing data.
In summary, we report suboptimal findings from the first two years of a comprehensive HIV
treatment program in rural north central Nigeria. Knowledge that less immunosuppression,
lower functional status, clinic of attendance, and more recent date of enrollment were
significantly associated with delayed ART initiation gives us specific targets for quality
improvement efforts. Community-based initiatives targeting at-risk malnourished patients,
many of whom also have reduced functional status, appear to be needed in such
settings.43–45 As PEPFAR moves from the emergency to the consolidation phase, with an
increasing proportion of scale-up activities occurring in rural settings, it becomes even more
important to employ program data in assessing performance and determining what changes
can be implemented that would make services more efficient, effective and sustainable by
local host governments in such settings.46
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Figure 1.
Flowchart depicting enrollment and ART eligibility for adult patients with HIV/AIDS,
Kwara and Niger states of Nigeria, 2009–2011.
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Figure 2.
Combination antiretroviral therapy initiation during the first 90 days post-enrollment, Kwara
and Niger states of Nigeria, 2009–2011.
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Table 1
Demographic characteristics of HIV-infected clients (age ≥15) by combination antiretroviral therapy initiation
status at 5 rural sites in Kwara and Niger states of Nigeria, 2009–2011
No ARTa ART in 90 days Combined P-value
(n=305) (n=869) (n=1174)
Clinic, n (%) <0.001
  GBRH 132 (43.3%) 545 (62.7%) 677 (57.7%)
  Kuta 42 (13.8%) 22 (2.5%) 64 (5.5%)
  LGH 28 (9.2%) 104 (12.0%) 132 (11.2%)
  SBSH 86 (28.2%) 153 (17.6%) 239 (20.4%)
  UMYMH 17 (5.6%) 45 (5.2%) 62 (5.3%)
Age (years)b 34 (28, 42) 34 (28, 40) 34 (28, 40) 0.3
Female 178 (58.4%) 555 (63.9%) 733 (62.4%) 0.1
Education, n (%) 0.1
  None 71 (33.2%) 233 (40.3%) 304 (38.4%)
  Started primary 11 (5.1%) 27 (4.7%) 38 (4.8%)
  Completed primary 35 (16.4%) 77 (13.3%) 112 (14.1%)
  Secondary 56 (26.2%) 149 (25.8%) 205 (25.9%)
  Post secondary 24 (11.2%) 37 (6.4%) 61 (7.7%)
  Qur'anic 17 (7.9%) 55 (9.5%) 72 (9.1%)
 Missingc 91 (29.8%) 291 (33.5%) 382 (32.5%)
Marital status, n (%) 0.3
  Divorced 6 (2.6%) 13 (2.2%) 19 (2.3%)
  Married 174 (74.4%) 474 (79.3%) 648 (77.9%)
  Separated 8 (3.4%) 29 (4.8%) 37 (4.4%)
  Single 22 (9.4%) 37 (6.2%) 59 (7.1%)
  Widowed 24 (10.3%) 45 (7.5%) 69 (8.3%)
 Missingc 71 (23.3%) 271 (31.2%) 342 (29.1%)
Occupation, n (%) 0.01
  Employed 75 (32.6%) 151 (25.9%) 226 (27.8%)
  Other 23 (10.0%) 90 (15.4%) 113 (13.9%)
  Retired 4 (1.7%) 2 (0.3%) 6 (0.7%)
  Student 9 (3.9%) 13 (2.2%) 22 (2.7%)
  Unemployed 119 (51.7%) 327 (56.1%) 446 (54.9%)
 Missingc 75 (24.6%) 286 (32.9%) 361 (30.7%)
Referral type, n (%) 0.054
  In-patient 1 (0.6%) 0 (0.0%) 1 (0.2%)
  Other 0 (0.0%) 2 (0.5%) 2 (0.3%)
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No ARTa ART in 90 days Combined P-value
(n=305) (n=869) (n=1174)
  PMTCT 5 (3.2%) 34 (8.1%) 39 (6.8%)
  VCT 148 (96.1%) 383 (91.4%) 531 (92.7%)
 Missingc 151 (49.5%) 450 (51.8%) 601 (51.2%)
Pregnant (enrollment) 10 (3.3%) 56 (6.4%) 66 (5.6%) 0.055
GBRH: Gawu Babangida Rural Hospital; LGH: Lafiagi General Hospital; SBSH: Sobi Specialist Hospital; UMYMH: Umaru Yar'adua Memorial
Hospital. ART: combination antiretroviral therapy. PMTCT: prevention of mother to child HIV transmission. VCT: voluntary counseling and
testing.
a
Includes 256 patients not initiating treatment prior to database cut date, and 49 initiating >90 days from enrollment.
bContinuous variables are reported as medians (interquartile range).
c
Percentages are computed using the number of patients with a non-missing value.
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Table 2
Distribution of clinical characteristics by combination antiretroviral therapy (ART) initiation among HIV/
AIDS patients eligible to start therapy, Kwara and Niger states of Nigeria, 2009–2011.
No ARTa ART in 90 days Combined P-value
(n=305) (n=869) (n=1174)
Height (cm)b 162 (156, 169) 162 (156, 167) 162 (156, 167) 0.6
 Missing, n (%)c 110 (36.1%) 197 (22.7%) 307 (26.1%)
Weight (kg)b 51 (45, 60) 53 (47, 60) 52 (46, 60) 0.06
 Missing, n (%)c 38 (12.5%) 25 (2.9%) 63 (5.4%)
Body mass index (kg/m2)b 19.3 (17.1, 21.9) 20.3 (18.3, 22.5) 20.1 (18.1, 22.4) 0.001
 Missing, n (%)c 114 (37.4%) 201 (23.1%) 315 (26.8%)
Functional status, n (%) <0.001
  Bedridden 14 (4.8%) 13 (1.5%) 27 (2.3%)
  Ambulatory 39 (13.4%) 72 (8.3%) 111 (9.6%)
  Working 237 (81.7%) 778 (90.2%) 1015 (88.0%)
  Missingc 15 (4.9%) 6 (0.7%) 21 (1.8%)
CD4+ count (cells/μL)*b 149 (69, 282) 159 (86, 250) 156 (81, 257) 0.9
CD4+ count category, n (%)
  ≤50/μL 45 (18.2%) 99 (11.9%) 144 (13.4%)
  51–200 104 (42.1%) 430 (51.8%) 534 (49.6%)
  201–350 71 (28.7%) 243 (29.3%) 314 (29.2%)
  >350 27 (10.9%) 58 (7.0%) 85 (7.9%)
  Missingc 58 (19.0%) 39 (4.5%) 97 (8.3%)
Hemoglobin (g/dL)b 10.2 (8.8, 11.8) 10.3 (9, 11.7) 10.2 (9, 11.7) 0.6
Hemoglobin category, n(%)
  <8 g/dL 31 (15.7%) 98 (12.6%) 129 (13.3%)
  8–10 g/dL 63 (32.0%) 248 (32.0%) 311 (32.0%)
  >10 g/dL 103 (52.3%) 430 (55.4%) 533 (54.8%)
  Missing 108 (35.4%) 93 (10.7%) 201 (17.1%)
Creatinine (mg/dL)b 0.8 (0.6, 1.2) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.7
 Missing, n (%)c 186 (61.0%) 596 (68.6%) 782 (66.6%)
WHO clinical stage, n (%) 0.003
  I 37 (12.6%) 162 (18.7%) 199 (17.2%)
  II 39 (13.3%) 140 (16.2%) 179 (15.4%)
  III 194 (66.0%) 527 (60.9%) 721 (62.2%)
  IV 24 (8.2%) 36 (4.2%) 60 (5.2%)
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No ARTa ART in 90 days Combined P-value
(n=305) (n=869) (n=1174)
  Missingc 11 (3.6%) 4 (0.5%) 15 (1.3%)
1-year mortalityd 21 (6.9%) 25 (2.9%) 46 (3.9%) 0.003
1-year loss to follow upd 119 (39.0%) 249 (28.7%) 368 (31.3%) 0.001
WHO = The World Health Organization.
a
Includes 256 patients not initiating treatment prior to database cut date, and 49 initiating >90 days from enrollment.
bContinuous variables are reported as medians (interquartile range).
c
Percentages are computed using the number of patients with a non-missing value.
d
Mortality and loss to follow up are at 1 year post-enrollment.
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Table 3
Logistic regression model: Failure to initiate combination antiretroviral therapy in 90 days among eligible
patients, Kwara and Niger states of Nigeria, 2009–2011 (n=1174).
Odds Ratio (95% CI)
Clinic
  GBRH (ref) 1
  Kuta 5.70 (2.99, 10.89)
  LGH 1.45 (0.86, 2.46)
  SBSH 2.46 (1.58, 3.85)
  UMYMH 0.84 (0.40, 1.76)
Age (per 5 yrs) 1.01 (0.94, 1.09)
Sex and pregnancy
  Female (ref) 1
  Pregnant Female 0.65 (0.31, 1.38)
  Male 1.32 (0.94, 1.87)
Education
  None (ref) 1
  Started primary 1.29 (0.59, 2.81)
  Completed primary 1.56 (0.91, 2.68)
  Secondary 1.43 (0.88, 2.33)
  Post secondary 2.08 (1.03, 4.20)
  Qur'anic 1.11 (0.58, 2.12)
Marital status
  Married (ref) 1
  Divorced 1.25 (0.43, 3.66)
  Separated 0.79 (0.33, 1.88)
  Single 1.31 (0.68, 2.54)
  Widowed 1.36 (0.78, 2.39)
Occupation
  Employed (ref) 1
  Other 0.98 (0.52, 1.82)
  Student 1.71 (0.61, 4.81)
  Unemployed 1.08 (0.66, 1.76)
BMI (per 1 kg/m2) 0.93 (0.88, 0.98)
Functional status
  Working (ref) 1
  Ambulatory 1.92 (1.15, 3.18)
  Bedridden 4.17 (1.63, 10.67)
CD4+ cell count (cells/μL)
  50 vs. 200 1.49 (0.93, 2.39)
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Odds Ratio (95% CI)
  350 vs. 200 2.10 (1.31, 3.35)
  500 vs. 200 3.02 (1.69, 5.39)
Hemoglobin (per 1 g/dL) 1.00 (0.91, 1.10)
WHO clinical stage
  I (ref) 1
  II 1.05 (0.60, 1.82)
  III 1.12 (0.70, 1.81)
  IV 1.16 (0.50, 2.71)
Month of enrollment
  June 2009 (ref) 1
  December 2009 1.01 (0.68, 1.48)
  June 2010 1.18 (0.64, 2.19)
  December 2010 2.13 (1.19, 3.81)
GBRH: Gawu Babangida Rural Hospital; LGH: Lafiagi General Hospital; SBSH: Sobi Specialist Hospital; UMYMH: Umaru Yar'adua Memorial
Hospital.
a
There is evidence that the association between the log-odds of delayed HAART initiation is non-linear with CD4+ count (p=0.021) and date of
enrollment (p=0.082). The last day of the month (e.g. June 30) is used to summarize odds ratios for month of enrollment.
b
There are 1174 patients included in this model. Missing values of baseline predictors are accounted for using multiple imputation.
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